Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

Condition	Intervention	Phase
Hypertension Left Ventricular Hypertrophy	Drug: amlodipine/benazepril	Phase IV

Further Study Details: 

Expected Total Enrollment:  168

Ages Eligible for Study:  55 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Males or female patients ≥ 55 years of age
• LVH as confirmed by echocardiogram
• Patients with high risk hypertension, currently treated or already taking antihypertensive medication

Exclusion Criteria:

• Renal artery stenosis
• Symptomatic heart failure or known ejection fraction < 40%
• Myocardial infarction or stroke within 6 months
• Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
• Pregnant or lactating females
• Cancer within the last 5 years

Please refer to this study by ClinicalTrials.gov identifier  NCT00139555

Novartis Pharmaceuticals      (862)778-8300 

New Jersey
      Novartis Pharmaceuticals, East Hanover,  New Jersey,  07936,  United States; Recruiting

Study chairs or principal investigators

Novartis Pharmaceuticals,  Study Director,  Novartis   

Study ID Numbers:  CCIB002FUS16
Last Updated:  August 30, 2005
Record first received:  August 29, 2005
ClinicalTrials.gov Identifier:  NCT00139555
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06